肝脏是晚期胃癌（GC）的常见转移部位。尽管诊断和治疗技术取得了显着进步，但胃癌肝转移（GCLM）患者的总体生存率仍然很低。精准肿瘤学在通过基因组测序和分子表征确定治疗靶点和增强我们对转移机制的理解方面取得了重大进展。因此，全面了解GCLM涉及的各种分子过程和全身治疗的基本原理对于开发新的治疗方法至关重要。本文旨在回顾关于 GCLM 的诊断、潜在生物标志物和针对 GCLM 多个分子过程的治疗的最新发现，旨在改善 GCLM 患者的治疗策略。版权所有 © 2024 Elsevier B.V. 保留所有权利。

The liver is a frequent site of metastasis in advanced gastric cancer (GC). Despite significant advancements in diagnostic and therapeutic techniques, the overall survival rate for patients afflicted with gastric cancer liver metastasis (GCLM) remains dismally low. Precision oncology has made significant progress in identifying therapeutic targets and enhancing our understanding of metastasis mechanisms through genome sequencing and molecular characterization. Therefore, it is crucial to have a comprehensive understanding of the various molecular processes involved in GCLM and the fundamental principles of systemic therapy to develop new treatment approaches. This paper aims to review recent findings on the diagnosis, potential biomarkers, and therapies targeting the multiple molecular processes of GCLM, with the goal of improving treatment strategies for patients with GCLM.Copyright © 2024 Elsevier B.V. All rights reserved.